Australian biotech market today 14.04.09
Tuesday, 14 April, 2009
The overall healthcare index was up on today’s trading at 2.30pm, following the trend of the rest of the indices. The All Ordinaries is up 2.5 per cent.
Cellestis (ASX:CST) is up 19c to $2.55 on the news that its TB diagnostic QuantiFERON-TB Gold In-Tube has received regulatory approval in Japan.
ChemGenex (ASX:CXS) is continuing to enjoy gains after announcing it had raised $10 million in secondary financing last week, up 4c to 46c.
Acrux (ASX:ACR) is up 2c to 65c, as is Biota (ASX:BTA) to 66c. Mesoblast (ASX:MSB) is up 5c to 85c.
Cochlear (ASX:COH) is up 68c, CSL (ASX:CSL) is down 11c and ResMed (ASX:RMD) is up 4c.
Pharmaxis (ASX:PXS) is down a steep 13c to $2.02 on reasonable volumes, as is Novogen (ASX:NRT), down 13.5 per cent to 48c. QRxPharma (ASX:QRX) is up 4c to 32c.
Progen (ASX:PGL) is up 3.8 per cent to 95c while Probiotec (ASX:PBP) is again enjoying healthy rises, up 6.2 per cent to $1.89.
Living Cell Technologies (ASX:LCT) is down 3.5c to 12c, while there has been some rare movement with LabTech Systems (ASX:LBT), up a cent to 14.5.
Overuse of inhalers can increase heart attack risk
Overuse of reliever inhalers is associated with higher risks of developing and dying from...
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
